Can Laparoscopic Cystectomy Improve Pregnancy Outcomes in Endometrioma? A Prospective Clinical Trial Study

Sedigheh Hosseinimousa, M.D.1, Leili Safdarian, M.D.1, Ashraf Aleyasin, M.D.1, Marzieh Aghahosseini, M.D.1, Marzieh Talebian, M.D.2

1. Department of Obstetrics and Gynecology and Reproductive, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Obstetrics and Gynecology, Kashan University of Medical Sciences, Kashan, Iran

Abstract

Background: The purpose of this prospective study was to compare the ovarian response and pregnancy outcomes in the infertile women with endometrioma undergoing assisted reproductive technologies (ART) in two groups, who were underwent laparoscopic cystectomy and received gonadotropin releasing hormone-agonist (GnRH-agonist) and who only received GnRH-agonist without any surgery.

Materials and Methods: In this prospective clinical trial study, 79 infertile women with asymptomatic endometriomas cyst (2-6 cm) were enrolled and randomly assigned to two groups. First group underwent laparoscopic cystectomy and received GnRH-agonist. Second group only received GnRH-agonist without any surgery. Following ovulation induction, all patients underwent intracytoplasmic sperm injection (ICSI). Different parameters such as the number of retrieved oocytes and embryos; were made our outcomes that analyzed using SPSS.

Results: The pregnancy rate, chemical and clinical, and live birth rate were higher in the combined group, although these differences were not statistically significant (48.48% vs. 30.8%, P=0.12, 36.36% vs. 25.6%, P=0.32, 36.36% vs. 23.1%, P=0.29). The number of injections, antral follicles, retrieved oocytes, mature oocytes, total embryos, transferred embryos and duration of stimulation were similar in two groups.

Conclusion: Laparoscopic cystectomy followed by receiving GnRH-agonist improves pregnancy outcomes in endometrioma prior to treatment with ART (registration number: IRCT201106116689N2).

Keywords: Cystectomy, Endometrioma, Infertility, GnRH-Agonist

Citation: Hosseinimousa S, Safdarian L, Aleyasin A, Aghahosseini M, Talebian M. Can laparoscopic cystectomy improve pregnancy outcomes in endometrioma? A prospective clinical trial study. Int J Fertil Steril. 2022; 16(3): 206-210. doi: 10.22074/IJFS.2021.521378.1066.

This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).

Introduction

Endometriosis is defined as endometrial glands and stroma that occur outside of the uterine cavity. Evidence suggests that peritoneal microenvironment is altered by immune cells, extracellular matrix metalloproteinase and pro-inflammatory cytokines, creating the conditions for abnormal endometrial cell proliferation and survival (1, 2). Infertility is the most important complaints in patients with endometrioma (ovarian endometriotic cyst). Endometriomas reduces the number of follicles and oocytes quality (3-5). In vitro fertilization (IVF) is considered as an effective method for treatment of infertility in patients with endometrioma (6). In the presence of endometrial cyst lower embryo quality, lower implantation rate and higher pregnancy complications were seen compared to the absence of endometrial cyst during IVF cycles (7). There are different treatment options for women with ovarian endometriotic cysts before IVF, including surgical treatment, medical treatment, and a combination of surgical and medical treatments and expectant management among infertile women (8-12).

The gonadotropin releasing hormone-agonist (GnRH-agonist) is one of the medical options. Since the endometrioma is an estrogen-dependent disorder, GnRH agonist can produce a hypo-estrogenic environment by suppression of the hypothalamus and improve pregnancy rates at IVF (12, 13).

The purpose of the present prospective study was to investigate the ovarian response and pregnancy outcomes after laparoscopic cystectomy plus GnRH- agonist versus GnRH- agonist alone among infertile women suffering from endometrioma.

Materials and Methods

Obtaining the formal approvals from the Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (90-02-30-14261-40996) this prospective
A clinical trial study was conducted in the Shariati Hospital of Tehran University of Medical Sciences, Tehran, Iran. Also, this study was restarted at the Iranian Registry of Clinical Trials (IRCT201106116689N2). All participants signed an informed consent before entering the study.

All women less than 40 years old with endometriosis and asymptomatic (without pain, torsion or rupture) endometriomial cyst (2 to 6 cm diameter) who were candidate to intracytoplasmic sperm injection (ICSI) were invited to this study. Who suffered of endometriomial cyst smaller than 2 cm or larger than 6 cm and who have history of surgery for endometrioma or other ovarian cysts were excluded. Also, women that their husbands suffered of azoospermia were omitted of this study.

In this prospective study, all infertile women who met the inclusion criteria were randomly assigned to two groups by a nurse from 2015 to 2019. This study was blinded for the nurse who randomized the participants and the statistician who analyzed the results. Randomization was done with an allocation sequence generated by block randomization by the trial statistician. All participants signed an informed consent before entering the study.

During this period, ninety-one of the women were assessed. Twelve of them did not have inclusion criteria. Six patients did not agree to be in a group and were excluded from the study. Finally, 73 participants were divided into 2 almost equal groups given a block size of 40.

Endometriosis was diagnosed in all patients previously by laparoscopy and sonography. Ultrasound diagnosis of endometrioma was present of round shaped homogeneous hypoechoic tissue. All transvaginal ultrasound examinations underwent by an expert physician gynecologist. The non-surgical diagnosis of endometrioma with transvaginal ultrasound is a valid method (14, 15). The combined group (laparoscopic cystectomy plus GnRH-agonist) underwent the laparoscopic cystectomy by a single experienced surgeon and the surgical technique consisted of resection of the endometriotic cyst wall. Then patients received 3 doses of Diphereline 3.75 mg (Beaufouipfen, France, IM) in 3 consecutive months. The GnRH-a alone group received three doses of Diphereline 3.75 mg (Beaufouipfen, France, IM) during three consecutive months.

Ovarian stimulation was conducted in two groups by Gonal F (Serono, Switzerland, 300-450 IU daily), ten days after the third injection of Diphereline. Seven days later, Gonal F was replaced by human menopausal gonadotropin (hMG, Ferring, Germany, 300-450 IU daily) until the observation of 18 mm follicles in the transvaginal ultrasound. With observation of at least two 18-mm follicles, human Chorionic Gonadotropin (hCG, Ferring Co, Germany, 10000 IU, IM) was injected and trans-vaginal oocyte retrieval was performed under general anesthesia after 36 hours. Fertilization was performed through ICSI. For blinding the study, counting the number of retrieved oocytes; determining the quality of oocytes and embryos and fertilization were performed by an embryologist who was not aware of the treatment groups. Transcervical embryo transfer was carried-out after three days. The chemical pregnancy was diagnosed based on the rising concentration of serum hCG levels. This measurement was performed in the Shariati hospital Laboratory service based on the standard serology method 14 days after embryo transfer. The clinical pregnancy was detected by observation of the pregnancy sac in transvaginal ultrasound, two weeks later of the hCG level rising.

Finally, the number of retrieved oocytes and embryos; quality of retrieved oocytes and embryos; fertilization rate, chemical and clinical pregnancy rates, abortion and live birth rates were compared between two groups by a statistician.

Statistical analysis

This study was blinded for the statistician who analyzed the results. All data were analyzed by SPSS software (Version 25, Armonk, New York, USA). The groups were initially compared on baseline variables with chi-square tests and independent samples t tests. Also, multiple logistic regression was used to examine the variables. Data were expressed as the mean ± standard deviation (mean ± SD) or percent (number). Statistical significance was defined as P<0.05.

Results

There were 79 patients who were divided into two groups randomly based on Bernoulli distribution and all of them underwent ovulation induction (Fig.1).

The demographic characteristics of two groups are shown in Table 1.
The IVF outcomes of two groups are shown in Table 2.

After laparoscopic cystectomy and receiving 3 doses of Diphereline, there were 16 chemical pregnancies in 33 patients. All of chemical pregnancies lead to live births (n=12, 3 twins /12); there were three abortions and one ectopic pregnancy (EP). Among 40 patients who received 3 doses of Diphereline before ART, there were 12 chemical pregnancies who lead to nine live births (3 twins); there were two abortions and one EP. Pregnancy outcomes of two groups are compared in Table 3.

Based on Table 1 Cyst size and CA125 level in combined group were higher; BMI and baseline FSH were lower than another group. Therefore, two groups were adjusted for BMI, Cyst diameter, FSH and CA125 levels in Table 4. There was no statistically significant difference between two groups regarding the live birth rate (Table 4).

### Table 1: Demographic characteristic of our study groups

| Characteristic                  | Combined group (n=33) | GnRH-a alone group (n=40) | P value |
|--------------------------------|-----------------------|---------------------------|---------|
| Mean age (years ± SD)          | 30.3 ± 4.61           | 31.44 ± 4.49              | 0.125   |
| BMI (kg/m²)                    | 23.91 ± 3.24          | 26.90 ± 3.78              | 0.004   |
| Cyst diameter (mm)             | 49.18 ± 11.99         | 31.87 ± 10.63             | <0.001  |
| Duration of infertility (years ± SD) | 6.21 ± 3.89          | 6.71 ± 4.30               | 0.309   |
| Bilateral cyst (%)             | 18                    | 8                         | 0.108   |
| Day 3 FSH (m IU/ml)            | 4.75 ± 2.22           | 6.58 ± 3.61               | 0.041   |
| Day 3 LH (m IU/ml)             | 5.14 ± 3              | 5.30 ± 5.25               | 0.872   |
| Day 3 estradiol (pg./ml)       | 56.24 ± 22.97         | 48.63 ± 37.34             | 0.435   |
| Day 21 progesterone (pg./ml)   | 10.88 ± 9.20          | 8.13 ± 9.02               | 0.215   |
| CA125 (m IU/ml)                | 51.9 ± 37.25          | 22.98 ± 15.37             | 0.004   |
| AMH (ng/ml)                    | 1.45 ± 0.95           | 1.70 ± 0.99               | 0.201   |

Crude and adjusted odds ratio for the association between the variables were reported as a confidence interval (CI) of 95%. Values are presented as mean ± SD. P<0.05 is defined for statistical significance. BMI; Body mass index, FSH; Follicle-stimulating hormone, LH; Luteinizing Hormone, GnRH; Gonadotropin-releasing hormone, and AMH; Anti mullerian hormone.

### Table 2: Comparison of IVF outcomes in our study groups

| Characteristic                  | Combined group (n=33) | GnRH-a alone group (n=40) | P value |
|--------------------------------|-----------------------|---------------------------|---------|
| Duration of stimulation, day    | 10.07 ± 2.67          | 10.42 ± 1.55              | 0.529   |
| Gonadotropin dose (IU)          | 3565.50 ± 1936.50     | 3578.25 ± 1593.75         | 0.797   |
| No. of antral follicles         | 10.78 ± 5.97          | 11.92 ± 5.38              | 0.173   |
| No. of retrieved oocytes        | 8.47 ± 6.52           | 9.55 ± 7.06               | 0.442   |
| No. of mature oocytes           | 4.62 ± 3.62           | 5.30 ± 3.93               | 0.380   |
| No. of total embryos            | 3.46 ± 2.77           | 3.62 ± 2.51               | 0.797   |
| No. of grade 1 embryos          | 2.34 ± 1.82           | 2.15 ± 1.62               | 0.682   |
| No. of transferred embryos      | 2.62 ± 1.59           | 2.38 ± 1.11               | 0.588   |
| Cancellation rate, n (%)        | 2 (6.06)              | 1 (2.5)                   | 0.398   |
| Fertilization rate (%)          | 79                    | 68                        | 0.471   |

Crude and adjusted odds ratio for the association between the variables were reported as a confidence interval (CI) of 95%. Values are presented as mean ± SD. P<0.05 is defined for statistical significance. IVF; In vitro fertilization and GnRH; Gonadotropin-releasing hormone.

### Table 3: Pregnancy outcomes in our study groups

| Characteristic                  | Combined group (n=33) | GnRH-a alone group (n=40) | P value |
|--------------------------------|-----------------------|---------------------------|---------|
| Chemical pregnancy rate         | 16 (48.48)            | 12 (30.8)                 | 0.124   |
| Clinical pregnancy rate         | 12 (36.36)            | 10 (25.6)                 | 0.325   |
| Live birth rate                 | 12 (36.36)            | 9 (23.1)                  | 0.292   |
| Abortion rate                   | 3 (9.09)              | 2 (5)                     | 0.740   |

Values are presented as n (%). P<0.05 is defined for statistical significance.
No adverse effect or harm related to the drug and/or operation was observed in these groups.

**Discussion**

Endometriosis is a chronic inflammatory estrogen-dependent disease in which the endometrial glands and stroma grow outside the uterus. Infertility is the most important complaints in the patients with endometrioma (ovarian endometriotic cyst). IVF is considered as an effective method for treatment of infertility in patients with endometriomas (6).

Removal of endometriomas before IVF in infertile women is controversial. Since oocyte retrieval is difficult in the presence of endometrioma and because of the risk of follicular fluid contamination many clinicians consider cystectomy prior to the ART. Furthermore, bloody component of endometriomas is an excellent cultural environment and following the puncture of the cyst during the oocyte retrieving procedure, there are some risks for infection and pelvic abscess formation (16).

On the other hand, because of pseudo cyst nature of endometrioma without any capsule, it invades the ovarian cortex and its resection will be accompanied with the resection of natural ovarian tissues. It was shown that primordial follicles were found in more than 50% of resected endometrial cysts (17). Additionally, the ischemic injury resulted from the electro-coagulation and the related local inflammation will injure ovaries. Through the evaluation of the numbers of antral follicles and oocytes and anti-Müllerian hormones, many studies have reported ovarian reserve reduction after cystectomy (18-20).

Based on the European Society of Human Reproduction and Embryology (ESHRE) guideline (12), GnRH agonists for a period of 3-6 months prior to treatment with ART is one of the medical options used for improvement of clinical pregnancy rates in the infertile women with endometriosis. Sallam et al. (21) study showed that 3-6 months of treatment with GnRH agonists before the start of IVF associated with 4 times increase in the pregnancy rate months of treatment with GnRH agonists before the start of endometriosis. Sallam et al. (21) study showed that 3-6 months of treatment with GnRH agonists before the start of IVF associated with 4 times increase in the pregnancy rate in stages III and IV of endometriosis in the all groups. In the Dong et al. (24) study, 153 women underwent laparoscopic cystectomy then IVF and 68 women with an endometriomral cyst directly received IVF procedure. They found no significant difference regarding the numbers of retrieved oocytes, embryos; chemical and clinical pregnancy rates and live birth rate, that their results were consistent with our results.

Zhao et al. (13) concluded that prolonged GnRH-a protocol after ovarian endometrioma cystectomy may be an optimal choice in patients with Diminished ovarian reserve.

In Lee’s study (25), patients with endometrioma were divided into three groups (surgery, aspiration of endometriomas and control) before ICSI, although the numbers of retrieved oocytes, were similar to our study. The clinical pregnancy rate was similar in all groups.

Alborzi et al. (26) enrolled patients with endometriosis in 3 groups: Letrozole group (2.5 mg/day, Femara, Novartis Pharma AG, Basel, Switzerland), GnRH-agonist group (Amp Diipherelin 3.75 mg, Beaufour Ipsen Pharma Paris, France) and control group. The chemical pregnancy rate in stages III and IV of endometriosis in the all groups were similar to our GnRH-agonist alone group.

Yang et al. (27) reported that GnRH-a for six months after laparoscopic surgery can improve pregnancy rate in endometriosis. The pregnancy rate in this group was significantly higher than laparoscopic surgery group (30.77% vs. 9.23%, P=0.002).

In the Barra et al. (28) and Laganà et al. (29) study, IVF outcomes improved in patients with endometriosis who received Dienogest (progestin) for 3 months.

In the present study, the rates of chemical and clinical pregnancy and live birth were higher in the combined group than GnRH-agonist alone group but these differences were not statistically significant.

Decleer et al. (23) divided patients with mild peritoneal endometriosis in the two groups. A group received GnRH agonist post-surgical for a 3-month period and the other group treated immediately after laparoscopy with stimulation for IVF. They detected no differences in the number of MII oocytes, embryos and pregnancy rate between their groups.

In the Dong et al. (24) study, 153 women underwent laparoscopic cystectomy then IVF and 68 women with an endometriomral cyst directly received IVF procedure. They found no significant difference regarding the numbers of retrieved oocytes, embryos; chemical and clinical pregnancy rates and live birth rate, that their results were consistent with our results.

Zhao et al. (13) concluded that prolonged GnRH-a protocol after ovarian endometrioma cystectomy may be an optimal choice in patients with Diminished ovarian reserve.

In Lee’s study (25), patients with endometrioma were divided into three groups (surgery, aspiration of endometriomas and control) before ICSI, although the numbers of retrieved oocytes, were similar to our study. The clinical pregnancy rate was similar in all groups.

Alborzi et al. (26) enrolled patients with endometriosis in 3 groups: Letrozole group (2.5 mg/day, Femara, Novartis Pharma AG, Basel, Switzerland), GnRH-agonist group (Amp Diipherelin 3.75 mg, Beaufour Ipsen Pharma Paris, France) and control group. The chemical pregnancy rate in stages III and IV of endometriosis in the all groups were similar to our GnRH-agonist alone group.

Yang et al. (27) reported that GnRH-a for six months after laparoscopic surgery can improve pregnancy rate in endometriosis. The pregnancy rate in this group was significantly higher than laparoscopic surgery group (30.77% vs. 9.23%, P=0.002).

In the Barra et al. (28) and Laganà et al. (29) study, IVF outcomes improved in patients with endometriosis who received Dienogest (progestin) for 3 months.

In the present study, the rates of chemical and clinical pregnancy and live birth were higher in the combined group than GnRH-agonist alone group but these differences were not statistically significant.

Our study had some limitations that should be mentioned. The sample size of this study was relatively small. Therefore, further randomized controlled trials are required to confirm the results of this study.
Conclusion
This study suggests that in the infertile women with endometriomatous cysts, laparoscopic cystectomy followed by receiving GnRH-agonist prior to treatment with assisted reproductive technologies (ART) improves the rates of chemical and clinical pregnancy and live birth.

Acknowledgments
The authors thank the infertility department and IVF center of the Shariati hospital, Tehran, Iran and Dr. Reza Pourmahmoodian for his assistance. We are grateful to the patients for their willing participation and cooperation with us. The present study was financially supported by the Vice-Chancellor of Tehran University of Medical Sciences, Tehran, Iran. The authors declare that there are no competing interests.

Authors’ Contributions
S.H., L.S.; Conceived and designed the experiments. A.A., M.A., S.H.; Performed the experiments. S.H., M.T.; Recorded the results. S.H.; Wrote the manuscript. All authors performed editing and approving the final version of this manuscript for submission.

References
1. Laganà AS, Garzon S, Götte M, Viganò P, Franchi M, Ghezzi F, et al. The pathogenesis of endometriosis: molecular and cell biology insights. Int J Mol Sci. 2019; 20(22): 5615.
2. Laganà AS, Salmeri FM, Ban Frangež H, Ghezzi F, Vrtučník-Bokal E, Granese R. Evaluation of M1 and M2 macrophages in ovarian endometriomas from women affected by endometriosis at different stages of the disease. Gynecol Endocrinol. 2020; 36(5): 441-444.
3. Yang C, Geng Y, Li Y, Chen C, Gao Y. Impact of ovarian endometrioma on ovarian responsiveness and IVF: a systematic review and meta-analysis. Reprod Biomed Online. 2015; 31(1): 9-19.
4. Ashraf M, Fakhri T, Kiani K, Sadeghi M, Akhoond MR. Impact of the endometrioma on ovarian response and pregnancy rate in in vitro fertilization cycles. Int J Fertil Steril. 2014; 8(1): 29-34.
5. Kitajima M, Khan KN, Harada A, Taniguchi K, Inoue T, Kaneuchi M, et al. Association between ovarian endometrioma and ovarian reserve. Front Biosci (Elite Ed). 2018; 10(1): 92-102.
6. Salamun V, Verdenik I, Laganà AS, Vrtučník-Bokal E. Should we consider integrated approach for endometriosis-associated infertility as gold standard management? rationale and results from a large cohort analysis. Arch Gynecol Obstet. 2018; 297(3): 613-621.
7. Somigliana E, Benaglia L, Paffoni A, Busnelli A, Viganò P, Vercellini P. Risks of conservative management in women with ovarian endometriomas undergoing IVF. Hum Reprod Update. 2015; 21(4): 486-499.
8. Leoncini P, Fritzel X, Revel-Delhom C, Ballester M, Boizé PA, Borghese B, et al. Management of endometriosis: CNGOF/HAS clinical practice guidelines - Short version. J Gynecol Obstet Hum Reprod. 2018; 47(7): 265-274.
9. Dunselman GA, Vermeulen N, Becker C, Cahazh-Jorge C, D’Hooghe T, De Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29(8): 1412-1418.
10. Zhao F, Lan Y, Chen T, Xin Z, Liang Y, Li Y, et al. Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study. J Ovarian Res. 2020; 13(1): 23.
11. Aas-Eng MK, Montanari E, Lieng M, Keckstein J, Huldestad G. Transvaginal sonographic imaging and associated techniques for diagnosis of ovarian, deep endometriosis, and adenomyosis: a comprehensive review. Semin Reprod Med. 2020; 38(2-3): 212-226.
12. Leonardi M, Espada M, Choi S, Chou D, Chang T, Smith C, et al. Transvaginal ultrasound can accurately predict the american society of reproductive medicine stage of endometriosis assigned at laparoscopy. J Minim Invasive Gynecol. 2020; 27(7): 1581-1587.
13. Villette C, Bourret A, Santulli P, Gayet V, Chapron C, de Ziegler D. Risks of tubo-ovarian abscess in cases of endometrioma and assisted reproductive technologies are both under- and overreported. Fertil Steril. 2016; 106(2): 410-415.
14. Fujii T, Wada-Hiraike O, Nagamatsu T, Harada M, Hirata T, Koga K, et al. Assisted reproductive technology pregnancy complications are significantly associated with endometriosis severity before conception: a retrospective cohort study. Reprod Biol Endocrinol. 2016; 14(1): 73.
15. Cranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017; 96(6): 633-643.
16. Turkoçuglú I, Melekoğlu R. The long-term effects of endometrioma surgery on ovarian reserve: a prospective case-control study. Gynecol Endocrinol. 2018; 34(7): 612-615.
17. Jiang D, Nie X. Effect of endometrioma and its surgical excision on fertility (Review). Exp Ther Med. 2020; 20(5): 114.
18. Sallam HN, García-Velasco JA, Dias S, Ariči A. Long-term psychical down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006; 2006(1): CD004635.
19. Zakaria H, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021; 27(1): 96-107.
20. Declerq W, Osmanagiaqolu K, Verschueren K, Comhaire F, Devroey P, RCT to evaluate the influence of adjuvant medical treatment of peritoneal endometriosis on the outcome of IVF. Hum Reprod. 2016; 31(6): 2017-2023.
21. Dong X, Wang R, Zheng Y, Xiong T, Liao X, Huang B, et al. Surgical treatment for endometrioma does not increase clinical pregnancy rate or live birth/ongoing pregnancy rate after fresh IVF/ICSI treatment. Am J Reprod Immunol. 2014; 72(2): 163-168.
22. Lee KH, Kim CH, Lee YJ, Kim SH, Chae HD, Kang BM. Surgical resection or aspiration with ethanol sclerotherapy of endometrioma before in vitro fertilization in infertile women with endometriosis. Obstet Gynecol Sci. 2014; 57(4): 297-303.
23. Alborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi S, Alborzi M. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (tripotrenol) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet. 2011; 284(1): 105-110.
24. Yang Y, Zhu W, Chen S, Zhang G, Chen M, Zhuang Y. Laparoscopic surgery combined with GnRH agonist in endometriosis. J Coll Physicians Surg Pak. 2019; 29(4): 313-316.
25. Barra F, Laganà AS, Scia C, Garzon S, Ghezzi F, Ferrero S. Pretreatment with dinogest in women with endometriosis undergoing IVF after a previous failed cycle. Reprod Biomed Online. 2020; 41(5): 859-868.
26. Laganà AS, Vitalle SG, Granese R, Palmara V, Ban Frangež H, Vrtučník-Bokal E, et al. Clinical dynamics of dinogest for the treatment of endometriosis: from bench to bedside. Expert Opin Drug Metab Toxicol. 2017; 13(8): 893-896.